

Date: 31.10.2023

To

**The Surveillance Department
BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001**

BSE Code-531146

Subject: Reply to the Clarification sought on Price Movement

This is with reference to clarification sought by BSE vide email L/SURV/ONL/PV/VK/ 2023-2024 / 401, we bring to the kind notice of the Exchange that there are no reportable events, information etc., that have a bearing on the operation/performance of the Company including price sensitive information which may result in the increase in the Prices of the shares of the Company under Regulation 30 of SEBI (LODR) Regulations, 2015.

The increase in the share price is purely market driven and the current market conditions; the management of the company is in no way connected with such increase in Price of shares.

Please be rest assured that the Company would always comply with the reporting requirements of the stock exchanges as provided in Regulations 30 of SEBI (LODR) Regulations, 2015, wherever applicable.

Kindly take the same on your records and oblige.

Thanking You

Yours truly,
For Medicamen Biotech Limited

**Parul Choudhary
Company Secretary & Compliance Officer
ACS: 44157**